Overview

A Research Study for Patients With Metastatic Renal Cell Carcinoma

Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the activity of FK228 in metastatic renal cell carcinoma (RCC) patients who have developed progressive disease (PD) following or during treatment with immunotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Celgene
Celgene Corporation
Treatments:
Romidepsin